Cited by 33T-cell and Retrovirus StudiesHIV Research and TreatmentHIV/AIDS drug development and treatment

Effect of Lamivudine on Transmission of Human T-Cell Lymphotropic Virus Type 1 to Adult Peripheral Blood Mononuclear Cells In Vitro

Open access
Balestrieri, Emanuela, Forte, Giancarlo, Matteucci, Claudia, Mastino, Antonio, Macchi, Beatrice·2002·Antimicrobial Agents and Chemotherapy

Abstract

The effects of lamivudine (3TC) on in vitro infection of peripheral blood mononuclear cells (PBMC) from healthy donors with human T-cell lymphotropic virus type 1 (HTLV-1) were investigated. Direct measures of viral replication (viral DNA, RNA, and protein) all gave similar, very high 50% inhibitory concentrations in comparison with those previously reported for zidovudine. Nevertheless, 3TC inhibited HTLV-1-driven long-term growth of infected PBMC in vitro at concentrations (6.25 μM) which had poor or no direct antiviral effects, suggesting that another mechanism may be playing a role.

Integrity signals

Registry

Crossref · 10.1128/aac.46.9.3080-3083.2002

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HTLV-1 resistance to 3TC was confirmed by multiple in vitro assays.

    “HTLV-1 resistance to 3TC was shortly confirmed by multiple in vitro assays [182]”

    From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [182]

  • The antiviral potency of 3TC was determined to be more than 100 times lower than AZT, discounting its potential for clinical relevancy.

    “and the antiviral potency was determined to be more than 100 times lower than AZT, discounting its potential for clinical relevancy.”

    From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [182]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Balestrieri, E., Forte, G., Matteucci, C., Mastino, A., & Macchi, B.
Affiliations
  • University of Messina (IT)
  • Department of Neuroscience
  • University of Rome Tor Vergata (IT)
  • Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Venue
Antimicrobial Agents and Chemotherapy
Published
2002-09
Volume
46
Issue
9
Pages
3080-3083
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2116093796
Cited by
33
References
1
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2020: 3 · 2018: 3 · 2017: 1 · 2013: 1
FWCI
0.88
Type
journal article
Language
en
Open access
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
lamivudine, zidovudine, HTLV-1, peripheral blood mononuclear cells, virus transmission, antiviral activity, viral replication inhibition, cell growth inhibition, HIV reverse transcriptase inhibitors
MeSH terms
DNA, Viral, Deltaretrovirus Infections, Humans, Monocytes, Virus Replication, Human T-lymphotropic virus 1, Coculture Techniques, Lamivudine, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review